Project Grant R21DA066004
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $1.5 million Project Grant to the University of Massachusetts Medical School on September 1, 2025, to conduct the "Improving Access to Medications for Opioid Use Disorder (MOUD) in Drug Courts Through Inter-Agency Collaboration: COLAAB Study" under the Drug Use and Addiction Research Programs (CFDA 93.279). The five-year project, concluding May 31, 2030, implements and evaluates a package of...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $438,950 under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Board of Regents of the University of Nebraska, operating through the University of Nebraska Medical Center (UNMC) in Omaha. The award, made on May 1, 2026, supports an R21 exploratory/developmental research grant with a project completion date of April 30, 2028. The research investigates the mechanisms underlying polysubstance use (PSU)...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Central Florida Board of Trustees a $1.59 million Project Grant on August 1, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to evaluate state policies facilitating emergency department-based treatment initiation for opioid use disorder (OUD). The project extends through May 31, 2030, and delivers two primary products: (1) creation of the first publicly available,...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded University of Colorado-Denver a Project Grant of $709,085 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct an implementation trial examining in-hospital opioid treatment program (OTP) intake facilitation. The project, awarded April 1, 2026 with a completion date of January 31, 2031, will implement a series of evidence-based implementation facilitation activities across four hospitals to...
- Federal Project Grant Award Summary New York University School of Medicine received a $2.09M project grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded July 1, 2025, with completion targeted for March 31, 2030. This research initiative characterizes complex Opioid Use Disorder (OUD) care trajectories and outcomes following acute service utilization through a population-based data linkage study. The project applies...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded The Johns Hopkins University a $198,164 Project Grant effective October 17, 2025, through May 14, 2027, to conduct research on improving access and linkage to substance use treatment for formerly incarcerated individuals. The project applies a complex systems approach to address barriers to Medications for Opioid Use Disorder (MOUD)...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University a Project Grant totaling $1,541,806 under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the STRONG (Informing Best Practices for Substance-Use Treatment with Real-World Evidence for People with Opioid Use Disorder and HIV) study. Effective from August 1, 2025 through April 30, 2030, this research initiative will comprehensively characterize opioid use...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $647,142 to The University of Kentucky Research Foundation under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct controlled research examining the impact of cannabis on opioid self-administration in individuals with opioid use disorder (OUD). The project, initiated February 15, 2026 and concluding November 30, 2030, addresses a critical public health gap by providing the first controlled data on...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $529,990 to Michigan State University (operating as Henry Ford Health+Michigan State University Health Sciences) on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test an adaptive psychological intervention designed to reduce prolonged opioid use among hospitalized patients recovering from musculoskeletal injuries. The intervention employs a tiered approach...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Massachusetts Medical School a $3.097 million Project Grant effective September 1, 2025, through May 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct "Improving Jail Response to the Overdose Crisis: A Hybrid Trial of Jail ECHO to Improve MOUD Implementation and Public Health Outcomes." The project addresses the critical gap in medication for...
The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $402,205 to the University of Nevada, Reno (Board of Regents of Nevada System of Higher Education) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a two-year research study examining medication for opioid use disorder (MOUD) treatment access and outcomes for dual Medicare and Medicaid enrollees. The research initiative, which commenced May 1, 2026 and concludes April 30, 2028, will analyze utilization and prescription claims data from 2021-2024 to determine whether enrollment in Dual Special Needs Plans (D-SNPs) improves MOUD access, treatment retention, and healthcare utilization outcomes for this vulnerable population. The study employs advanced econometric methods including propensity score weighting and instrumental variable approaches to address selection bias and will assess direct and indirect relationships between plan enrollment and outcomes such as emergency department visits and inpatient hospitalizations. The research products will include comprehensive analyses of MOUD treatment patterns (buprenorphine, methadone, and extended-release naltrexone) utilizing National Quality Forum quality measures, as well as examination of how plan-level heterogeneity in integrated benefits and supplemental wrap-around services addressing social determinants moderates treatment and utilization outcomes. Findings will contribute to understanding how integrated Medicare-Medicaid coverage structures can address systemic barriers to opioid addiction treatment and reduce overdose-related mortality and morbidity among dual-eligible beneficiaries.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $402.2k | 4/30/26 |